National Cardiovascular Center Harapan Kita Jakarta Indonesia
Jakarta, Indonesia
NCT Number: NCT05976204
Tetralogy of Fallot (ToF) were cyanotic congenital heart disease with chronic hypoxia which increases the risk of exacerbated inflammatory response in ToF primary repair. Various studies have recently shown inflammatory biomarkers to predict morbidity and mortality in hypoxemic patients, but they are not readily available and expensive.This study aims to compare the prognostic value of neutrophil-lymphocyte ratio (NLR), absolute lymphocyte count (ALC), and thrombocyte-lymphocyte ratio (TLR) in predicting ToF primary repair outcomes. This was a retrospective observational study on ToF primary repair in National Cardiovascular Center Harapan Kita between Januari 2020 until December 2022. Preoperative NLR, ALC, and TLR were derived from blood test obtained <14 days before surgery. The primary endpoints were redo surgery, 30-day mortality, and complications. The secondary endpoints were hospital length of stay (HLOS) and postoperative LOS.
Looking for future studies?
Notify MeUp to 18 year
All sexes
Observational
Jakarta, Indonesia
This was a retrospective observational study on tetralogy of Fallot (ToF) primary repair in National Cardiovascular Center Harapan Kita between Januari 2020 until December 2022. The preoperative demographic data included were patients' gender, age, weight, oxygen saturation, and associated diagnosis other than ToF. The preoperative data of complete blood count and differential count must be tested from the most recent peripheral blood samples taken no later than 14 days before the surgery. The data obtained were the number of days of the most recent blood test including the leukocyte count, percentage neutrophil, percentage and absolute lymphocyte count, thrombocyte count, as well as the derived variables such as neutrophil lymphocyte ratio (NLR) ratio and thrombocyte lymphocyte ratio (TLR). The intraoperative data included were the use of cardiopulmonary bypass (CPB), CPB time, aortic cross-clamp (AOX) time, and the total duration of surgery. Patients were evaluated and followed-up for any complications and postoperative mortality during the same hospital stay until discharge. Patients were then followed up for any cause of mortality within 30 days postoperative.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
ToF primary repair for patients with ToF
Time frame: From the initial primary ToF until the discharge of the patients or until 2 weeks after the operation, whichever came first
Redo surgery was defined as additional or corrective surgery after the initial primary ToF repair within the same hospital admission.
Time frame: Until 30 days postoperative
Mortality intraoperative or postoperative
Time frame: From the initial primary ToF until the discharge of the patients or until 2 weeks after the operation, whichever came first
Complication was defined as any adverse events that arised during the operation or postoperative until the discharge of the patient.
Time frame: From the initial primary ToF until the discharge of the patients or until 12 weeks after the operation, whichever came first
Hospital length of stay (HLOS) was defined as the duration of stay in the hospital from the initial admission to discharge.
Time frame: From the initial primary ToF until the discharge of the patients or until 12 weeks after the operation, whichever came first
Longer postoperative LOS was defined as hospitalization of more than 5 days from the period of surgery until postoperative discharge (based on our center).
National Cardiovascular Center Harapan Kita Hospital Indonesia
Other
Prognostic Value of Neutrophil-Lymphocyte Ratio (NLR), Absolute Lymphocyte Count (ALC), and Thrombocyte-Lymphocyte Ratio (TLR) in Predicting the Outcomes of Tetralogy of Fallot Primary Repair
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02968264
Cardiovascular Abnormalities, Cardiovascular Diseases
Orlando, Florida, United States
View Trial DetailsNCT01762124
Cardiovascular Abnormalities, Cardiovascular Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT00243776
Cardiovascular Abnormalities, Cardiovascular Diseases
Atlanta, Georgia, United States
View Trial DetailsNCT05122962
Cardiovascular Abnormalities, Cardiovascular Diseases
Rochester, Minnesota, United States
View Trial Details